Please refer to Phase I studies for more clinical trial opportunities.

Melanoma

Adjuvant Therapies

<table>
<thead>
<tr>
<th>Trial Details</th>
<th>Stage 2b or 2c</th>
<th>Stage 2b, 2c or 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB# 19679</td>
<td>Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase III Study</td>
<td>IRB#11848 Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence</td>
</tr>
</tbody>
</table>

IRB# 21536 A Phase 2 trial of AU-011 via suprachoroidal administration designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma

IRB#15661 A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma

IRB #16883 A Phase III, Randomized Study of Nivolumab with Ipilimumab vs. Ipilimumab or Nivolumab Monotherapy Post-resection

Moderna

A Phase II randomized study of adjuvant immunotherapy with Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

IRB# 21882 A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempedaladesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

CROSS-DISEASE TRIALS:

IRB# TBD EAY131 (MATCH)
IRB# TBD S1609 (DART)

Melanoma

Uveal Melanoma

IRB# 19679 Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase III Study

Stage 3 or 4 Resectable

http://www.ohsu.edu/research/rda/so/knight.php
## Melanoma

**Stage 3 or 4, Unresectable**

### Mutation Specific

| IRB# 19667 | A Phase II, Open-Label, Randomized, Multicenter Trial of Enzalutamide+ Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAFV600-Mutant Melanoma Brain Metastasis |

### Non-Mutation Specific

| IRB# 19687 | A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma |

| IRB# 19943 | A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma |

| IRB# 19285 | A Phase Ib/2 Study of PV-10 Intralésional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma |

---

1/31/2022

http://www.ohsu.edu/research/rda/so/knight.php
IRB 22389: A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab in Patients with Advanced Solid Tumors

IRB 22483: A Randomized, Controlled Study to Assess the Efficacy of the Tryl Software Application vs. Standard Reminders on the Response and Adherence Rate of Melanoma Community Registry Members

IRB 23891 Natera Bespoke IO

http://www.ohsu.edu/research/rda/so/knight.php